Impact of IFNL4 genotype on interferon-stimulated gene expression during daa therapy for Hepatitis C
New directly acting antivirals (DAAs) provide very high cure rates in most patients infected by hepatitis C virus (HCV). However, some patient groups have been relatively harder to treat including those with cirrhosis or infected with HCV genotype 3. In the recent BOSON trial, genotype 3, cirrhotic patients receiving a 16 week course of sofosbuvir and ribavirin had a sustained virologic response rate (SVR) of around 50%. In cirrhotic patients, IFNL4 CC genotype was significantly associated wi...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Pubs id:
- Local pid:
- Deposit date:
- Copyright holder:
- Ramamurthy et al
- Copyright date:
Copyright © The Authors. H epatology published by Wiley Periodicals, Inc. on behalf of American Association for the Study of Liver Diseases.
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
If you are the owner of this record, you can report an update to it here: Report update to this record